Form 4: Teva Director Amir Elstein Reports Share Transactions

Teva Pharmaceutical Industries Ltd. director Amir Elstein has reported the acquisition of 14,492 ordinary shares through restricted share units that vested on June 5, 2026.

Summary

• Amir Elstein, a Director at Teva Pharmaceutical Industries Ltd., reported a transaction on June 5, 2026.
• The transaction involved the acquisition of 14,492 ordinary shares.
• These shares were acquired through the vesting of restricted share units (RSUs).
• The RSUs were originally granted on June 5, 2025, and vested on June 5, 2026.
• Following this transaction, Elstein beneficially owns 2,118,455 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine insider transaction related to executive compensation rather than a significant strategic event.

Positives

• Director acquisition of shares indicates confidence in the company.
• Vesting of restricted share units represents a form of executive compensation and aligns management interests with shareholders.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a director, are common in the pharmaceutical industry and can provide insights into management's perception of the company's value.

Stakeholder Impact

• Shareholders: The transaction may be viewed positively as it indicates a director's continued investment and potential confidence in the company's future performance.
• Employees: The vesting of RSUs is a component of executive compensation, aligning management's interests with those of the company and its shareholders.

Key Dates

Keywords

Teva Pharmaceutical Industries, Amir Elstein, Form 4, SEC Filing, Insider Transaction, Ordinary Shares, Restricted Share Units, Beneficial Ownership